Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 19/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 19/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 18/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 7/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 7/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8674956 | 0.92 | ADRA2A (0.84) | ADRA2AADRA2CADRA2BADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL7033434 | 0.86 | ADRA2A (0.74) | ADRA2AADRA2CADRA2BADRA1DADRA1A | |
| SCHEMBL8117260 | 0.82 | ADRA2A (0.69) | ADRA2AADRA2CADRA2BADRA1DADRA1A | |
| SCHEMBL7742994 | 0.82 | ADRA2A (0.69) | ADRA2AADRA2CADRA2BADRA1DADRA1A | |
| SCHEMBL5816998 | 0.82 | ADRA2A (0.68) | ADRA2AADRA2CADRA2BADRA1DADRA1A | |
| SCHEMBL13516592 | 0.82 | ADRA2A (0.68) | ADRA2AADRA2CADRA2BADRA1DADRA1A | |
| SCHEMBL11185457 | 0.81 | ADRA2A (0.68) | ADRA2AADRA2CADRA2BADRA1DADRA1A | |
| SCHEMBL11480097 | 0.81 | ADRA2A (0.68) | ADRA2AADRA2CADRA2BADRA1DADRA1A | |
| SCHEMBL7091961 | 0.79 | ADRA2A (0.65) | ADRA2AADRA2CADRA2BADRA1DADRA1A | |
| SCHEMBL4672878 | 0.79 | ADRA2A (0.65) | ADRA2AADRA2CADRA2BADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3153626-A | — | — | None | — | — | JP | disclosed |
| US-20170216282-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | GALDERMA LABORATORIES INC | 2017-08-03 | — | — | US | disclosed |
| US-20160220565-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | Galderma Laboratories, L.P. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160166569-A1 | METHOD FOR TREATING SKIN THICKENING | GALDERMA RESEARCH AND DEVELOPMENT (FR) | 2016-06-16 | — | — | US | disclosed |
| US-9186358-B2 | Combination therapy for treating or preventing an inflammatory skin disorder | Galderma Laboratories, L.P. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150313896-A1 | METHOD FOR TREATING CELL PROLIFERATION DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-11-05 | — | — | US | disclosed |
| US-20150202202-A1 | COMPOUNDS, FORMULATIONS, AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS | Galderma Laboratories, L.P. (US) | 2015-07-23 | — | — | US | disclosed |
| US-9072739-B2 | Method for treating psoriasis | Galderma Laboratories, L.P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150098917-A1 | METHOD FOR PREVENTING OR TREATING SKIN TUMOR | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-04-09 | — | — | US | disclosed |
| US-8993571-B2 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | Galderma Laboratories, L.P. (US) | 2015-03-31 | — | — | US | disclosed |
| US-5561132-A | ADMINISTERING TO ALTER RATE OF FLUID TRANSPORT IN GASTROINTESTINAL TRACT | ALLERGAN (US) | 1996-10-01 | — | — | US | disclosed |
| US-5552403-A | ANTIISCHEMIC AGENTS | ALLERGAN (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0723447-A1 | METHODS FOR USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES | Allergan (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995016449-A1 | 6-(2-IMIDAZOLINYLAMINO)QUINOXALINE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1995-06-22 | — | — | WO | disclosed |
| WO-1995016449-A1 | 6-(2-IMIDAZOLINYLAMINO)QUINOXALINE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1995-06-22 | — | — | WO | disclosed |
| EP-0426390-B1 | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure | ALLERGAN INC (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1995010280-A1 | METHODS FOR USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES | ALLERGAN (US) | 1995-04-20 | — | — | WO | disclosed |
| JP-H03153626-A | REDUCTION OF MAINTENANCE OF INTRAOCULAR PRESSURE USING (2-IMIDAZOLIN-2-YLAMINO)QUINOXALINE | ALLERGAN INC | 1991-07-01 | — | — | JP | disclosed |
| US-5021416-A | Glaucoma | ALLERGAN, INC. (US) | 1991-06-04 | — | — | US | disclosed |
| EP-0426390-A2 | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure | ALLERGAN, INC. (US) | 1991-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166569-A1 | METHOD FOR TREATING SKIN THICKENING | CUTA, EDNRB, TBXA2R | ADRA2A 8/4885ADRA2C 15/4885ADRA2B 9/4885 |
| US-20150098917-A1 | METHOD FOR PREVENTING OR TREATING SKIN TUMOR | ADRB2, ADRA2A, ADRA2C | ADRA2A 2/4885ADRA2C 3/4885ADRA2B 4/4885 |
| US-20150313896-A1 | METHOD FOR TREATING CELL PROLIFERATION DISORDERS | MKI67, ADRB1, ADRA1D | ADRA2A 8/4885ADRA2C 16/4885ADRA2B 9/4885 |
| US-20150202202-A1 | COMPOUNDS, FORMULATIONS, AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS | HRH4, HRH1, HRH3 | ADRA2A 120/4885ADRA2C 272/4885ADRA2B 67/4885 |
| US-20170216282-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | HRH4, HRH1, HRH3 | ADRA2A 120/4885ADRA2C 272/4885ADRA2B 67/4885 |
| US-20160220565-A1 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders | HRH4, HRH1, HRH3 | ADRA2A 120/4885ADRA2C 272/4885ADRA2B 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.